louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02768610: Use of Preanesthetic Dexmedetomidine in Elderly, Treated-hypertensive Patients
Official title: Effects of Preanesthetic Dexmedetomidine on Hemodynamic Responses to Endotracheal Intubation in Elderly Patients Being Treated for Hypertension: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Perioperative Care
Keywords: dexmedetomidine
Lead sponsor: DongGuk University
Sponsor class: OTHER
First posted: 2016-05-11
Enrollment: 2
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Background: Dexmedetomidine is an alpha 2 adrenergic agonist with sedative, anxiolytic, and analgesic properties. This study was designed to evaluate the inhibitory effects of preoperative 0.5 μg/kg dexmedetomidine on hemodynamic responses caused by endotracheal intubation in elderly patients being treated for hypertension.

Methods: Forty elderly (≥ 65 years) treated-hypertensive patients of American Society of Anesthesiologists physical status II undergoing elective noncardiac surgery were randomly and assigned to two groups. Group C received normal saline and group D received 0.5 μg/kg dexmedetomidine intravenously over 10 min just before endotracheal intubation. Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and heart rate (HR) were recorded preoperatively at ward, immediately after study drug administration, and at 1, 3, and 5 minutes after endotracheal intubation.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists physical status II
* Scheduled for elective noncardiac surgery
* Being treated with anti-hypertensive medication

Exclusion Criteria:

* Endotracheal intubation attempted more than twice
* Morbidly obese (BMI \> 35 kg/m2)

Primary outcomes:
measure: Changes in systolic blood pressure
timeFrame: 2 minutes before intubation and 1, 3, 5 minutes after intubation
measure: Changes in diastolic blood pressure
timeFrame: 2 minutes before intubation and 1, 3, 5 minutes after intubation
measure: Changes in mean arterial pressure
timeFrame: 2 minutes before intubation and 1, 3, 5 minutes after intubation
measure: Changes in heart rate
timeFrame: 2 minutes before intubation and 1, 3, 5 minutes after intubation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: DongGuk universit hospital Gyeongju hospital
name: Miwoon Kim, M.D., Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03765710: Role of Dietary Protein Intake in Elderly Adults
Official title: Role of Dietary Protein Intake on Whole Body Protein Balance in Elderly Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Protein Overload
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2018-12-05
Enrollment: 8
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The investigators examined the effects of dietary protein intake in a mixed meal at two levels of protein amount on whole body protein metabolisms in older adults.

Detailed description: The investigators determined the total anabolic response to an amount of protein intake commonly eaten with dinner (70g) as compared with the amount required to maximally stimulate muscle protein synthesis (35g). Men and women, ages \> 60 years will be studied under two levels of protein intake in mixed meals in random order (35g or 70g protein in isocaloric mixed meals). For two days prior to each stable isotope tracer study, subjects' dietary intake of calories and protein will be stabilized by providing subjects their entire diets. On the third day, a 8-hr metabolic study will be conducted in the UAMS Reynolds Institute on Aging (IOA) to determine the total anabolic response to the particular amount of beef intake, which will be repeated with the other amount of protein in mixed meal after a minimum 7-day washout interval. The investigators measured whole body protein kinetics, muscle fractional synthetic rate, and plasma amino acid profile.

Eligibility criteria: Inclusion Criteria:

* Men and women, ages \> 60 years

Exclusion Criteria:

* History of diabetes
* History of malignancy in the 6 months prior to enrollment
* History of gastrointestinal bypass surgery (Lapband, etc)
* History of a chronic inflammatory condition or disease (Lupus, HIV/AIDS, etc)
* Pregnant females
* Subjects who do not or will not eat animal proteins
* Subjects who cannot refrain from consuming protein or amino acid supplements during their participation in this study
* Subjects who report regular resistance exercise (more than once per week)
* Hemoglobin less than 9.5 mg/dL at the screening visit
* Platelets less than 150,000 at the screening visit
* Subjects who are not willing or able to suspend aspirin for several days prior to their muscle biopsies
* Subjects who have been prescribed a blood-thinning medication (Coumadin, lovenox, heparin, Plavix, etc.)
* Concomitant use of corticosteroids (ingestion, injection or transdermal)
* Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician

Primary outcomes:
measure: Changes in whole body anabolism
timeFrame: Change before and after a mixed meal intake for approximately 8 hours
measure: Changes in skeletal muscle synthetic rate
timeFrame: Change before and after a mixed meal intake for approximately 8 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02792010: Feasibility and Reproducibility of T1 Rho MRI in the Evaluation of Hip Cartilage
Official title: Feasibility and Reproducibility of T1 Rho MRI in the Evaluation of Hip Cartilage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Keywords: T1rho MRI
hip
cartilage
Healthy participants
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-06-07
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Hip osteoarthritis is a frequent and invalidating disease. Early detection of cartilage modifications could provide better patient treatment. The T1rho MRI sequence allows the quantification of the cartilage signal that is correlated to modifications of the cartilage matrix, notably of the proteoglycans. The primary objective is to evaluate normal values of hip cartilage in vivo using T1rho MRI in healthy subjects and the reproducibility of the measurements. T1rho and T2 mapping sequences were acquired twice during the same session with 30 minutes interval to see if values were modified after a 30 minutes delay in a supine position. The secondary objective was to assess the correlation between T1rho and T2 values.


Eligibility criteria: Inclusion Criteria:

* BMI \<30
* Accepting to participate in the study and signed the written informed consent
* Covered by a health insurance system

Exclusion Criteria:

* Pregnant woman or risk of pregnancy
* MRI contraindication
* Protected adults
* Language barrier
* Previous or current hip pain

Primary outcomes:
measure: Quantification of the cartilage signal at T1rho MRI
timeFrame: Up to one month after inclusion (Visit 1)
Secondary outcomes:
measure: Quantification of the cartilage signal at T1rho MRI
timeFrame: 15 (+/- 7) days after visit 1 (Visit 2)
measure: Quantification of the cartilage signal at T2 MRI
timeFrame: Up to one month after inclusion (Visit 1)
measure: Quantification of the cartilage signal at T2 MRI
timeFrame: 15 (+/- 7) days after visit 1 (Visit 2)
measure: Presence of cartilage lesions
timeFrame: Up to one month after inclusion (Visit 1)
measure: Presence of cartilage lesions
timeFrame: 15 (+/- 7) days after visit 1 (Visit 2)
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon - Hôpital Edouard Herriot Pavillon B Radiologie
Study officials:
affiliation: Hospices Civils de Lyon
name: Jean-Baptiste PIALAT, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05931510: Release Versus Post Isometric Relaxation Among Futsal Players With Shin Splints
Official title: Effects of Myofascial Release Versus Post Isometric Relaxation Among Futsal Players With Shin Splints
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Shin Splint
Keywords: Shin splint
Myofascial release
Post isometric relaxation
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-07-05
Enrollment: 32
Sex: MALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to determine the effects of myofascial release versus post isometric relaxation among futsal players with shin splints

Detailed description: Previous literature did not compare the combined effects of both myofascial release and post isometric relaxation technique inn sgin splints patients so the purpose of this study is self-explanatory, with the basic goal of comparing these two techniques to determine their effects on patient Pain, and Functional disability thus improving overall performance of the futsal players.This study will be helpful in proposing proper treatment for shin splint, to make people aware of the condition rehabilitation and improving performance of the futsal players undergoing the condition. Thus it will be useful for the betterment of the players overall health and wellbeing.

Eligibility criteria: Inclusion Criteria:

* Subjects have leg pain with exertion of more than 1 or 2 hours
* Participants age 20-30 years
* Participants have MTSS for more than 2 weeks
* Subjects have No previous history of trauma to legs
* Subject having Local pain on lower anterior leg Gradual cessation of the offending activity

Exclusion Criteria:

* • Subjects have medical history of systemic disease

  * Subjects have Medical history of cardiovascular disease
  * Participants with History of metastatic diseases
  * Any trauma or pathology of lower limb Participants having Neuropathy of lower extremity

Primary outcomes:
measure: Numeric pain rating scale
timeFrame: 3 months
measure: Lower extremity functional scale
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Model town hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Nosheen Manzoor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02036710: Location of GLP-1 Release
Official title: Location of Glucagon-Like Peptide (GLP)-1 Release
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Keywords: GLP-1
PYY
Leptin
Duodenal Switch
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2014-01-15
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population consisted of morbidly obese individuals who had decided to undergo open duodenal switch surgery

Brief summary: Background: Physicians do not have a unified, scientifically tested theory of causation for obesity and its comorbidities, nor do they have explanations for the mechanics of the metabolic/bariatric surgery procedures. Integral to proffered hypotheses are the actions of the hormones glucagon-like peptide (GLP-1), peptide YY (PYY), and leptin.

Study objective: To obtain blood levels of GLP-1, PYY, and leptin after stimulation of the terminal ileum and cecum by a static infusion of a food hydrolysate in morbidly obese patients undergoing a duodenal switch procedure.

Methods: Plasma levels of GLP-1, PYY, and leptin were obtained at 0, 30, 60, 90, and 120 minutes after instillation of 240 ml of a food hydrolysate into the ileum or cecum.


Eligibility criteria: Inclusion Criteria:

* Any patient who was qualified and approved for bariatric surgery and elected to undergo open duodenal switch procedure.

Exclusion Criteria:

Primary outcomes:
measure: GLP-1
timeFrame: 2 hours
measure: peptide YY (PYY)
timeFrame: 2 hours
measure: Leptin
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Henry Buchwald, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04828512: Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis
Official title: Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Cirrhosis
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2021-04-02
Enrollment: 1015
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with cirrhosis without previous diabetes history

Brief summary: Disorders of glucose metabolism, such as impaired glucose intolerance (IGT) and diabetes mellitus (DM), frequently occur in cirrhosis. However, it has been underestimated when fasting plasma glucose (FPG) levels are considered. We aimed to evaluate who needs to be undertaken a 75-g oral glucose tolerance test (OGTT) to find underlying subclinical diabetes.


Eligibility criteria: Inclusion Criteria:

* Liver cirrhosis
* Admitted to a hospital

Exclusion Criteria:

* Previously confirmed DM
* Being treated for DM
* Standard risk factors of T2DM, such as high body mass index and family history of diabetes
* Symptoms of DM, such as increased thirst and the need to urinate
* Either hepatocellular carcinoma or other malignancy
* Hepatic failure or uncontrolled decompensation \[that is, refractory ascites or active variceal hemorrhage\]
* Significant illnesses such as sepsis that may have interfered with glucose metabolism
* Pancreatic dysfunction such as acute/chronic pancreatitis that may have affected glucose metabolism.

Primary outcomes:
measure: Survival
timeFrame: through study completion, an average of 3 year
Secondary outcomes:
measure: major complications of cirrhosis
timeFrame: through study completion, an average of 3 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05439512: Orbital Floor Fracture Repair by Titanium Mesh Via Transantral Approach.
Official title: Feasibility of Patient-specific Titanium Mesh Via A Transantral Approach for Repair of Orbital Floor Fractures.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Orbital Fractures
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-06-30
Enrollment: 7
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate the feasibility of CAD/CAM osteosynthesis mesh through a transantral surgical approach in the Repair of orbital floor fractures by means of clinical and radiographic findings.

Detailed description: A CAD/CAM osteosynthesis mesh through a transantral approach should assumingly provide accurate reconstruction of the orbital volume and anatomy while eliminating the usual morbidity of lower eyelid approaches during orbital reconstruction.

Eligibility criteria: Inclusion Criteria:

* Patients with recent unilateral orbital floor fracture indicated for internal reconstruction -
* (isolated or in combination with other facial fractures)
* with existing or estimated enophthalmos based on radiographs and a contra-lateral healthy non-operated orbit.

Exclusion Criteria:

* Delayed cases (more than 2 weeks)
* previously operated cases
* bilateral orbital floor fracture.

Primary outcomes:
measure: enophthamus
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry,Cairo University
Study officials:
References:
Clinical trial NCT02063412: Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens
Official title: The Impact of Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens in the Management of Advanced Esophago-gastric Cancer in Hong Kong
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Gastric Cancer
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
name: Queen Elizabeth Hospital, Hong Kong
name: Princess Margaret Hospital, Hong Kong
First posted: 2014-02-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients who were diagnosed with AEGC and were prescribed with either XELOX-based or FOLFOX4-based chemotherapy treatment

Brief summary: The objective of this study is to compare the possible time savings from reduction of nursing and pharmacy time to manage AEGC patients using capecitabine-based regimens versus traditional intravenous chemotherapy in the Hong Kong public hospital setting.

Detailed description: Advanced esophageal and gastric cancer (AEGC) have ranked in the top 10 cancer-related cause of death worldwide, with approximately one million new cases each year. Over half of new cases are in East Asia. The traditional chemotherapy for AEGC remains on intravenous (IV) fluorouracil (5-FU), cisplatin, and the anthracyclines. Trials favoured the combined use of 5-FU and cisplatin for superior efficacy and quality of life in AEGC patients. Recent years, oral chemotherapy has a more practical and economic advantages over IV regimen. It is understandable that patients prefer oral regimens as long as the clinical efficacy is maintained. Oral treatment strategy preserves quality of life for AEGC patients. In addition, it may also have additional cost saving in the nursing and pharmacy time. It is because a significant amount of time can be saved in both nursing and pharmacy for the preparation and administration of IV chemotherapy However, there is a lack of local data to demonstrate the impact of pharmacy and nursing care utilizing capecitabine-based regimen comparing to traditional IV chemotherapy in MCRC patients of Hong Kong.

Eligibility criteria: Inclusion Criteria:

1. Aged 18 or above
2. Diagnosed with AEGC and were prescribed with either XELOX-based or FOLFOX4- based chemotherapy treatment

Exclusion Criteria:

1. Persons \< 18 years of age;
2. Pregnant or lactating women;
3. Persons related unequally to investigators (e.g. student, employee);
4. Special population (e.g. prisoner, mentally, congnitively disabled);
5. Patients who refused to sign consent or not willing to participate.

Primary outcomes:
measure: Composite preparation, dispensing, and administration time
timeFrame: Up to 6 months after initiation of chemotherapy
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Chinese University of Hong Kong
name: Vivian WY Lee, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01560312: Renal Denervation in Refractory Hypertension
Official title: Renal Denervation - Hope for Patients With Refractory Hypertension?
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Hypertension
Resistant to Conventional Therapy
Keywords: Renal denervation
Resistant hypertension
Spironolactone
Long-term Outcome
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
Collaborators: name: General University Hospital, Prague
name: University Hospital Olomouc
name: Cardiocenter Podlesí, Trinec, Czech Republic
First posted: 2012-03-22
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Open, multicenter, randomized study is enrolling patients in 3 sites in Czech Republic. Patients with refractory hypertension will be randomized in 1:1 manner either to renal denervation plus optimal medical antihypertensive treatment without spironolactone or to antihypertensive treatment alone including spironolactone if not contraindicated. The primary end-point is change in Systolic and Diastolic Blood Pressure (BP) between baseline and 1 year after randomization evaluated by 24-hours BP monitoring. Expected enrollment is 120 patients. Patients follow-up is planned for 3 years.


Eligibility criteria: Inclusion Criteria:

* Refractory hypertension with office SBP \> 140 mmHg
* SBP \> 130 during 24-hours Holter blood pressure monitoring
* Treatment with the least 3 antihypertensive medications including diuretics in optimal doses
* Age \> 18 years
* Signed informed consent

Exclusion Criteria:

* Secondary forms of hypertension
* Chronic renal disease (serum creatinine \> 200 umol/l)
* Pregnancy
* History of myocardial infarction or stroke in last 6 months
* Severe valvular stenotic disease
* Anatomic abnormalities and variants of renal artery including aneurysms, severe stenosis, reference diameter \< 4 mm or length \< 20 mm
* Increased bleeding risk (thrombocytopenia \< 50, INR \> 1.5)

Primary outcomes:
measure: Blood pressure difference
timeFrame: 6 months
Secondary outcomes:
measure: Blood pressure differences similar to primary outcome
timeFrame: 1 year, 2 years, 3 years
measure: Change of blood laboratory parameters and renal function
timeFrame: 6 months, 1, 2, 3 years
measure: Post-denervation renal anatomy assessment
timeFrame: 1 year
Other outcomes:
Locations:
city: Olomouc
country: Czechia
facility: Cardiocenter, University Hospital Olomouc
city: Prague
country: Czechia
facility: Jiri Widimsky
city: Trinec
country: Czechia
facility: Cardiocenter Podlesi
Study officials:
affiliation: Charles University, Prague, Czech Republic
name: Petr Widimsky, Prof, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: General University Hospital
name: Jiri Widimsky, Prof.MD.
role: PRINCIPAL_INVESTIGATOR
References: